TAVI in LOW RISK in the REAL WORLD (TAVI IN LOW R)
調査の概要
状態
状態
条件
条件
詳細な説明
Severe aortic stenosis is the most common valvular heart disease worldwide. Its prevalence increases with age and is estimated to affect approximately 2% of the population aged 70-80 and as many as 9% of adults over 80 years of age.¹ Given the progressive aging of the population and the ever-increasing life expectancy, its prevalence will continue to rise, representing not only a topic of scientific interest but also a significant public health issue. In the past, the treatment of severe aortic stenosis was strictly the domain of cardiac surgery, and the gold standard was aortic valve replacement via open-heart surgery. In 2002, however, in an effort to offer a compassionate treatment option to patients considered high-risk or even ineligible for traditional surgery, transcatheter aortic valve replacement (TAVI) was introduced. The PARTNER study was the first randomized trial to evaluate the use of a balloon-expandable valve (Sapien - Edwards). The study consisted of two cohorts: Cohort A, comprising patients at high surgical risk, demonstrated that TAVI was non-inferior to SAVR in terms of 1-year all-cause mortality.
And a second cohort, Cohort B, which enrolled patients who were not considered suitable candidates for surgical aortic valve replacement (SAVR) and demonstrated a reduction in the rate of all-cause mortality or rehospitalization with transcatheter aortic valve implantation (TAVI) compared with standard medical therapy.² The efficacy and safety of transcatheter aortic valve replacement were quickly recognized by the ESC/EACTS and ACC/AHA, which incorporated this technique into their guidelines in 2012 and 2014, respectively. TAVI was in fact recommended as a Class I recommendation for patients ineligible for cardiac surgery and as a Class IIA recommendation for high-risk patients. At the same time, the CoreValve Extreme Risk Pivotal and CoreValve US Pivotal studies demonstrated the safety and efficacy of a self-expanding valve in the treatment of aortic stenosis (CoreValve - Medtronic); and in the second study, even its superiority over traditional surgery.
Since then, several studies have been conducted to demonstrate the safety and efficacy (non-inferiority) of TAVI compared to SAVR, even in intermediate-risk patients, including PARTNER 2 (which used a second-generation Sapien XT valve) and SURTAVI (CoreValve and Evolut R). Once again, guidelines were not long in coming, and in 2017, the ESC/EACTS classified the use of TAVI in patients with increased risk (intermediate or high) as Class I. Two further studies, PARTNER 3 and Evolut Low Risk, subsequently demonstrated the non-inferiority of TAVI compared to SAVR, thereby securing approval in Europe and the United States for use in low-risk patients. These valves have distinguished themselves by achieving excellent results across various outcomes in low-risk patients. In fact, Sapien 3 demonstrated superior results in terms of 1-year mortality and stroke rates and a lower need for pacemaker implantation compared to Evolut, which, however, achieved better hemodynamic performance within its own studies. Currently, registries showing TAVI outcomes in real-world patients are few and limited; therefore, it is important to assess whether data on outcomes in low-risk all-comers outside of trial settings align with trial results.
Patients included in the retrospective part of the study will be enrolled from January 2021 through September 2024 and will account for approximately two-thirds of the patients enrolled in the CCM.
Patients included in the prospective part of the study will be enrolled from October 2024 through August 2025.
For all patients deemed eligible, data will be collected regarding the screening/baseline visit, procedural data, discharge, and 12-month follow-up
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
BS
-
Brescia、BS、イタリア、25124
- Fondazione Poliambulanza Istituto Ospedaliero, Unità Emodinamica
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Patients aged 18 years or older
- Patients with severe symptomatic aortic valve stenosis undergoing TAVI.
- Patients considered to be at low surgical risk, defined as an STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) score of less than 4% and no major organ damage.
Exclusion Criteria:
- Patients who required emergency aortic valve replacement for any reason
- Need for conversion to SAVR during the procedure
- Patients who refused to consent to participate in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Patients with symptomatic severe aortic valve stenosis
Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
All-cause mortality
時間枠:Up to 12 months
|
Up to 12 months
|
|
Occurrence of stroke
時間枠:Up to 12 months
|
Up to 12 months
|
|
Rehospitalization for cardiovascular causes
時間枠:Up to 12 months
|
Up to 12 months
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Occurrence of major or minor bleeding
時間枠:Up to 12 months
|
Up to 12 months
|
|
Implantation of a permanent pacemaker
時間枠:Up to 12 months
|
Up to 12 months
|
|
Development of paroxysmal or permanent atrial fibrillation
時間枠:Up to 12 months
|
Up to 12 months
|
|
Infectious causes requiring prolonged monitoring in the hospital
時間枠:Up to 12 months
|
Up to 12 months
|
|
Presence of significant paravalvular or intravalvular regurgitation
時間枠:Up to 12 months
|
Up to 12 months
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。